Accessibility Menu

SpyGlass Pharma

(NASDAQ) SGP

Current Price$22.82
Market Cap$671.01MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2026)-24%
5 YearN/A
1 YearN/A
1 Month+10%

SpyGlass Pharma Financials at a Glance

Market Cap

$671.01MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$43.60

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.71 (Low)

Price

$22.82

Volume

169,487.877

Open

$19.91

Previous Close

$22.52

Daily Range

$19.53 - $22.92

52-Week Range

$16.00 - $32.44

Estimated Earnings Date

Aug 13, 2026

SGP News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About SpyGlass Pharma

Industry

Pharmaceuticals

Employees

65

CEO

Patrick Mooney

Headquarters

Aliso Viejo, CA 92656, US

SGP Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-123.53%

Return on Capital

N/A

Return on Assets

-10.21%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$671.01MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

33.43M

Volume

169.49K

Avg. Volume

97.55K

Financials (TTM)

Gross Profit

-$534.73K

Operating Income

-$29.04M

EBITDA

-$25.84M

Operating Cash Flow

-$22.88M

Capital Expenditure

-$1.10M

Free Cash Flow

-$23.97M

Cash & ST Invst.

$251.00M

Total Debt

$1.61M

SpyGlass Pharma Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$318.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$671.01MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$10.32M

N/A

Employees

65

N/A

Net Income

-$13.82M

N/A

EBITDA

-$13.50M

N/A

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$251.00M

N/A

Total Debt

$1.61M

N/A

Accounts Receivable

$653.00K

N/A

Inventory

$0.00

N/A

Long Term Debt

$1.61M

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-10.21%

N/A

Return on Invested Capital

-11.54%

N/A

Free Cash Flow

-$14.22M

N/A

Operating Cash Flow

-$13.54M

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,570.77+0.00%
^DJIDJI
$52,660.66+0.00%
^IXICNASDAQ
$26,285.09+0.00%
BTCBitcoin
$63,842.00+0.01%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOFISoFi Technologies
$18.78+0.01%
PATHUiPath
$11.68-0.01%
FRMIFermi
$6.59-0.10%
INTCIntel
$109.84-0.02%

Questions About SGP

What is the current price of SpyGlass Pharma?

SpyGlass Pharma is trading at $22.52 per share.

What is the 52-week range for SpyGlass Pharma?

Over the past 52 weeks, SpyGlass Pharma has traded between $16.00 and $32.44.

How much debt does SpyGlass Pharma have?

As of the most recent reporting period, SpyGlass Pharma reported total debt of $1.61M.

How much cash does SpyGlass Pharma have on hand?

SpyGlass Pharma reported $238.90M in cash and cash equivalents in its most recent financial results.

What is SpyGlass Pharma’s dividend yield?

SpyGlass Pharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.